Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Neuphoria Therapeutics Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −1 vs. Q4 2025
- Shares held
- 1.76M
- +312.8K (+21.6%) vs. Q4 2025
- Total value
- $7.15M
- +$1.55M (+27.6%) vs. Q4 2025
- New holders
- 6
- 5 more added
- Sold out
- 7
- 1 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEUP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $8.71M |
| Q1 2026 | 19 | $7.15M |
| Q4 2025 | 21 | $5.69M |
| Q3 2025 | 15 | $2.30M |
| Q2 2025 | 9 | $1.26M |
| Q1 2025 | 7 | $935.4K |
| Q4 2024 | 8 | $273.4K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Neuphoria Therapeutics Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 58 | $236 | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 202 | $822 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,316 | $9.43K | 0.00% | +664+40.2% | Added |
| Merck & Co., Inc. | 10,027 | $40.8K | 0.01% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 11,222 | $45.7K | 0.00% | +15+0.1% | Added |
| Virtu Financial LLC | 12,033 | $49.0K | 0.00% | +12,033 | New |
| Boothbay Fund Management, LLC | 14,000 | $57.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 19,331 | $78.7K | 0.00% | +19,331 | New |
| FNY Investment Advisers, LLC | 26,500 | $107.0K | 0.05% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 30,000 | $122.1K | 0.01% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 33,589 | $136.7K | 0.00% | +33,589 | New |
| Ikarian Capital, LLC | 47,443 | $193.1K | 0.03% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 52,007 | $211.7K | 0.00% | +34,704+200.6% | Added |
| Squadron Capital Management LLC | 76,728 | $312.3K | 0.12% | +76,728 | New |
| Vanguard Capital Management LLC | 98,516 | $401.0K | 0.00% | +98,516 | New |
| Balyasny Asset Management LLC | 142,183 | $578.7K | 0.00% | +142,183 | New |
| Shay Capital LLC | 151,010 | $614.6K | 0.09% | −18,049−10.7% | Reduced |
| AdvisorShares Investments LLC | 155,367 | $632.3K | 0.12% | +21,173+15.8% | Added |
| Lynx1 Capital Management LP | 875,328 | $3.56M | 0.56% | +1000.0% | Added |
| Diadema Partners LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −16,597−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −14,750−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −13,403−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,008−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,400−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |